VolitionRx says finger-prick sepsis test tracks lab Nu.Q NETs assay in clinical study

VolitionRx reported clinical study results showing its finger-prick, point-of-care sepsis test aligned with its established lab assay.

Findings support rapid bedside identification of higher-risk sepsis patients, reducing reliance on centralized laboratories.

Decentralized testing could broaden commercial reach, with the company targeting a $3.8 billion global NETosis-testing market.

Management flagged expansion potential in lower-income countries with limited lab infrastructure, citing roughly 166 million annual sepsis cases worldwide.